You are now leaving consilienthealth.ie

You are about to exit the Consilient Health website to visit an independent third party website which is not under the control of Consilient Health. Consilient Health makes no warranties or representations of any kind as to the accuracy, completeness, reliability or usefulness of any information contained in third party sites and shall have no liability for any loss or damage of any kind that may arise from your use of such content or information.

Inclusion of any third party link does not imply an endorsement or recommendation by Consilient Health Ltd.

Please click ok if you wish to continue to the third party website or click cancel if you wish to return to altavita.ie.

OK

Link to: Blissel
Vaginal atrophy How Blissel works Dosing Useful resources FAQs Back to main site

BlisselⓇ is simply dosed for both initial and maintenance therapy

How to start therapy and maintenance1

BlisselⓇ can be started any time after the manifestation of symptoms.

Initial treatment:

One applicator-dose of vaginal gel per day for 3 weeks (suitably at bedtime).

Maintenance treatment:

One applicator-dose of vaginal gel twice a week (suitably at bedtime) is recommended. An evaluation of treatment continuation after 12 weeks should be carried out by the physician.

For initiation and continuation of treatment of post-menopausal symptoms, the lowest effective dose for the shortest duration should be used.

For oestrogen products for vaginal application of which the systemic exposure to the oestrogen remains within the normal postmenopausal range, it is not recommended to add a progestagen.

Missed doses1

A missed dose should be administered as soon as remembered, unless it is more than 12 hours overdue. In the latter case the missed dose should be skipped, and the next dose should be administered at the normal time.

See the summary of product characteristics for full prescribing information.1

Precautions 1

  • For the treatment of postmenopausal symptoms, local estrogen therapy should only be initiated for symptoms that adversely affect quality of life.
  • In all cases, a careful appraisal of the risks and benefits should be undertaken at least annually and HRT should only be continued as long as the benefit outweighs the risk.
  • BlisselⓇ 50 micrograms/g vaginal gel must not be combined with estrogen preparations for systemic treatment, as there are no studies of safety and risks with estrogen concentrations attained in combination treatment.
  • Intravaginal applicator may cause minor local trauma, especially in women with serious vaginal atrophy.

For full information see the summary of product characteristics.1.

  1. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics.

Summary of Product Characteristics can be found at www.medicines.ie

The information on this website is intended for Republic of Ireland residents only.
IE-CH-1363 Date of Preparation August 2023

© Consilient Health Ltd. All rights reserved.

Adverse Events / Product Complaints or for Pharmacovigilance or Medical enquiries please contact:
E: drugsafety@consilienthealth.com
T: (01) 205 7766
All other queries: (01) 205 7760

  • Careers
  • Transfer of Value
  • Privacy Policy
  • Cookies
  • Terms
  • Sitemap
Scroll to top

This site is intended for Healthcare Professionals registered in Ireland. By clicking to enter this site you are confirming that you are a Healthcare Professional registered in Ireland.

Continue Cancel